Markus Enzelberger

Markus Enzelberger is a prominent figure in the biotechnology sector, currently serving as a Board Member at SixPeaks Bio and a Partner at Versant Ventures. He is based in the Greater Munich Metropolitan Area and has extensive experience in drug development and biotechnology.

Professional Background

• Current Roles:

  • Board Member at SixPeaks Bio AG since its inception in July 2022, where he contributes to the strategic direction of the company, which focuses on research and development in the biotech field.2
  • Partner at Versant Ventures since July 2020, where he plays a crucial role in launching new biotech companies through their Ridgeline Discovery Engine.35

• Previous Experience:

  • Enzelberger was the Chief Scientific Officer (CSO) at MorphoSys AG from November 2017 until March 2020, where he was instrumental in advancing the company's research initiatives.36
  • He held various senior roles at MorphoSys AG starting from March 2002, including Senior Vice President and Vice President.13

Education

Markus Enzelberger holds a Postdoctoral degree in Applied Physics from the California Institute of Technology (Caltech) and a Ph.D. in Chemistry from the University of Stuttgart, reflecting his strong academic background that supports his professional endeavors in biotechnology.1

Contributions to Biotechnology

Enzelberger is recognized for his expertise in protein engineering and drug discovery, having been involved in launching several biotech startups through Versant Ventures. His work at Ridgeline Discovery has led to the establishment of multiple innovative companies focused on developing novel therapeutics.45

Overall, Markus Enzelberger's extensive experience and leadership roles position him as a key player in the biotech industry, particularly in the areas of drug development and venture capital investment.